Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.83
(
0.44%
)
US TECH 100
23,497.41
(
0.42%
)
Dow Jones
46,669.88
(
0.36%
)
Brent Oil
107.07
(
-1.93%
)
Bitcoin
68,833.81
(
-0.25%
)
News Focus
News Focus
Post# of 516882
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Investor2014

Send PM Follow Ignore
Followers 65
Posts 27712
Boards Moderated 0
Alias Born 11/23/2016

Investor2014

Re: tradeherpete post# 333081

Sunday, 10/17/2021 7:04:42 AM

Sunday, October 17, 2021 7:04:42 AM

Post# of 516882
In any case Anavex will have to file data from the trials. For that to happen the trials first have to readout. All this is true also for provisional or accelerated approval.

As for a surrogate endpoint biomarker, I can’t quite see we have one.

The primary and secondary endpoints as defined in the trial protocols has a good chance of being met.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News